diabetes medicine semaglutide FDA Clears For Cardiac Risk Reduction in Diabetic Patients This medicine also may slow gastric emptying after eating What to know about Ozempic

2 Under the authority of Section 199.17(f)(3) of Title 32, Code of Federal Regulations TRICARE Home Delivery

Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)

Why are these patients most at risk

The efficacy of survodutide was compared with open-label semaglutide (up to 1.0 mg qw)

Omeprazole, lisinopril, warfarin, metformin, digoxin, the combined oral contraceptive ethinyl estradiol/levonorgestrel, rosuvastatin and furosemide have all been evaluated for drug interactions with semaglutide